Scortichini Matteo, Paoletti Martina, Ragonese Angela, Cuneo Antonio, Vignetti Marco, Zinzani Pier Luigi
Economic Evaluation and Health Technology Assessment, Centre for Economic and International Studies, Faculty of Economics, University of Rome Tor Vergata, Rome - Italy.
Section of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara - Italy.
Glob Reg Health Technol Assess. 2025 Mar 11;12:80-88. doi: 10.33393/grhta.2025.3365. eCollection 2025 Jan-Dec.
In Italy, Non-Hodgkin Lymphomas (NHL), including Waldenström's Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL), are among the most common hematologic cancers. These conditions mainly affect the elderly, who often have multiple comorbidities, complicating management and imposing significant burdens on patient quality of life and healthcare systems.
This study aimed to estimate the economic burden of selected B-cell lymphomas in Italy, providing insights for decision-makers to improve patient management and resource allocation.
Data from the Italian Hospital Discharges Records (SDO) and the National Institute for Social Security were analyzed to estimate direct healthcare costs and social security costs from 2016 to 2019.
A total of 93,712 hospital discharges were recorded, with MZL being the most common diagnosis, followed by CLL and WM. Most patients were male, and the 70-79 age group was most prevalent. MZL had the highest costs, followed by CLL and WM. Adverse events notably increased total expenditures, with variations across different pathologies. Direct healthcare costs totaled 533.6 million euros, while social security costs amounted to 240.9 million euros.
This study highlights the significant economic burden of selected B-cell lymphomas in Italy. Effective management strategies are crucial for reducing costs and optimizing resource allocation in the healthcare system.
在意大利，非霍奇金淋巴瘤（NHL），包括华氏巨球蛋白血症（WM）、边缘区淋巴瘤（MZL）和慢性淋巴细胞白血病（CLL），是最常见的血液系统癌症之一。这些疾病主要影响老年人，他们往往有多种合并症，使治疗复杂化，并给患者的生活质量和医疗系统带来沉重负担。
本研究旨在估计意大利特定B细胞淋巴瘤的经济负担，为决策者改善患者管理和资源分配提供见解。
分析了意大利医院出院记录（SDO）和国家社会保障研究所的数据，以估计2016年至2019年的直接医疗费用和社会保障费用。
共记录了93712例出院病例，其中MZL是最常见的诊断，其次是CLL和WM。大多数患者为男性，70-79岁年龄组最为普遍。MZL的费用最高，其次是CLL和WM。不良事件显著增加了总支出，不同病理类型存在差异。直接医疗费用总计5.336亿欧元，而社会保障费用为2.409亿欧元。
本研究强调了意大利特定B细胞淋巴瘤的巨大经济负担。有效的管理策略对于降低医疗系统成本和优化资源分配至关重要。
